Introduction
Recalls happen more often than most people outside the industry assume, and far more often than any single company wants to talk about publicly. A labeling error, an out-of-specification result discovered after distribution, a component defect found in post-market surveillance, a contamination event, a software issue in a connected device: all of these can trigger a recall, and when one starts, regulatory affairs sits at the center of it. This is not a role spotlight on a job title so much as a look at a process that a lot of regulatory affairs careers eventually touch directly, whether or not the word recall ever appears in the job description.
Recalls are stressful precisely because they combine a genuine patient or user safety question with a hard deadline and a lot of people outside regulatory affairs who want a fast answer. Understanding the actual workflow, rather than the vague sense that someone handles it, is useful both for people who may end up owning one and for anyone trying to understand what post-market regulatory work really involves.
How a Recall Decision Gets Made
A recall almost never starts in regulatory affairs. It usually starts with quality: a complaint pattern, an internal deviation, a failed stability result, or a finding during an audit or inspection that raises a safety or quality question about product already in the field. Quality and regulatory then work together on a health hazard evaluation, assessing the actual risk the issue poses to patients or users if the product stays on the market or in use.
That evaluation feeds directly into classification. For drugs, FDA uses a three-tier system: Class I for a reasonable probability of serious adverse health consequences or death, Class II for a situation where use may cause temporary or medically reversible harm, and Class III for a violation unlikely to cause adverse health consequences. Medical devices follow a similar risk-tiered logic under FDA's recall framework, and in the EU, MDR and IVDR impose their own field safety corrective action and vigilance reporting obligations that follow a comparable risk-based logic. Regulatory affairs is usually the function that proposes the classification and defends it to the agency, because getting it wrong in either direction, understating a real risk or overreacting to a minor one, has consequences.
Correction or Removal: Choosing the Right Strategy
Not every recall means pulling product entirely off the market. FDA's framework, and the equivalent EU field safety corrective action structure, distinguishes between a correction, where the problem is fixed in place, such as a software update pushed to a device already in the field or a revised set of instructions for use mailed to customers, and a removal, where the product actually has to come back or be destroyed. Regulatory affairs, working with quality and engineering or manufacturing, helps decide which strategy actually addresses the risk, because choosing a correction when a removal was really warranted can turn what should have been a contained action into a much bigger problem once regulators or the field notice the fix was insufficient.
This decision also shapes the recall strategy's depth: how far down the distribution chain the action needs to reach. A recall might stop at the wholesale or distributor level if the issue is unlikely to be relevant by the time product reaches an individual patient, or it might need to reach the retail level, the hospital pharmacy level, or in some cases individual patients or users directly. Regulatory affairs helps define that depth based on the health hazard evaluation and has to defend the choice if a health authority asks why the action did not go further.
Notifying the Health Authority
Once a company decides to recall, or FDA requests one, there are specific notification obligations, and regulatory affairs owns making sure they are met on time. For drugs, this generally means notifying FDA and providing information the agency needs to make its own classification determination and post the recall in its public enforcement reports. For devices, manufacturers have separate reporting obligations tied to corrections and removals, and in many cases a Medical Device Report may also be required if the underlying issue involved a malfunction or adverse event.
This part of the job is almost entirely about precision under time pressure: getting the facts right, describing the affected product and lots accurately, and communicating a timeline the company can actually meet, because a recall notification is a formal regulatory record, not an internal memo.
Writing the Recall Communication
Someone has to tell the people who have the product what to do about it, and that letter is regulatory affairs' work, done in close coordination with legal, quality, and communications. A recall letter to distributors, pharmacies, hospitals, or in some cases directly to patients has to explain the issue honestly, state clearly what action the recipient needs to take (return the product, stop use, destroy it, quarantine it), and do so without either minimizing the risk or triggering unnecessary panic. Getting this tone right, technically accurate and genuinely clear at the same time, is a specific writing skill that regulatory affairs develops over repeated exposure to this kind of work.
Tracking Effectiveness
A recall is not finished when the letter goes out. FDA generally expects the company to run effectiveness checks, confirming that the people who received the recall notice actually understood it and took the required action, at a level appropriate to the risk classification. Regulatory affairs tracks the reconciliation of how much affected product has been returned, destroyed, or otherwise accounted for against how much was distributed, and keeps the file organized well enough to survive a later inspection question about how the recall was run.
This is unglamorous, detail-heavy work, but it is exactly the kind of documentation discipline that separates a recall handled well from one that becomes an inspection finding of its own a year later.
Effectiveness checks themselves usually follow one of a few standard approaches: a telephone call to the affected account confirming they received and understood the notice, a written confirmation returned to the company, or in some cases a personal visit for the highest-risk situations. Regulatory affairs, working with quality, decides which level is appropriate given the classification and drafts the actual verification script or form, since a poorly worded confirmation request can produce a technically completed check that does not actually prove the account understood what action was required.
Closing the Recall
Once the company can show the recall has been effective and the affected product has been adequately accounted for, regulatory affairs prepares the request to terminate the recall and works with the health authority toward a formal closure. That closure, and the complete file behind it, becomes part of the company's regulatory history and is exactly the kind of record an inspector or auditor may ask to review during a future site inspection.
Coordinating a Multi-Market Recall
Recalls rarely stay within a single country's regulatory framework once a product is distributed internationally. A drug or device sold in the United States, the EU, and several other markets under separate marketing authorizations may need separate notifications filed on different timelines to different health authorities, each with its own classification logic, its own documentation format, and sometimes its own opinion about how serious the issue actually is. Regulatory affairs typically coordinates this centrally, making sure the core facts, the affected lots, the root cause, and the corrective action, stay consistent across every market's filing even though the specific regulatory mechanics differ, since inconsistent explanations across countries are exactly the kind of thing that draws additional scrutiny from any single regulator who notices the discrepancy.
This part of the job also means managing the reality that different health authorities can reach different classification conclusions about the same underlying issue, and regulatory affairs has to be able to explain that divergence internally without it reading as the company hiding something in one filing versus another.
What This Work Demands
Recall work rewards people who stay calm and organized when everyone around them is not. It requires holding a lot of moving pieces (classification, notification deadlines, communication drafts, reconciliation tracking) without losing track of any one of them, and it requires being willing to tell executives an answer they do not want to hear, such as a classification level that is more serious than the company hoped, or a timeline that cannot be compressed just because leadership wants the issue closed quickly. People who have run a recall well tend to carry that credibility with them for the rest of their careers, because it is one of the clearest demonstrations of regulatory judgment under real pressure.
Conclusion
A recall is one of the few moments where regulatory affairs work becomes visible to the outside world, in a public FDA enforcement report or a headline, even though the actual work behind it is mostly invisible: a health hazard evaluation, a classification decision, a notification filed on time, a letter written carefully, and a file tracked to closure. It is not a specialty most people plan a career around, but almost every experienced regulatory professional has a recall story, and the skills it builds, precision, composure, and cross-functional coordination under a hard deadline, transfer directly to nearly everything else the job involves.